The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Open accessAbstract
Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes, resulting in increased activity of the MYC pathway. In primary breast tumors, MYC signaling did not predict response to neoadjuvant chemotherapy but was associated with poor prognosis. We exploit the increased MYC expression found in triple-negative breast cancers by using a synthetic-lethal approach dependent on cyclin-dependent kinase (CDK) inhibition. CDK inhibition effectively induced tumor regression in triple-negative tumor xenografts. The proapoptotic BCL-2 family member BIM is up-regulated after CDK inhibition and contributes to this synthetic-lethal mechanism. These results indicate that aggressive breast tumors with elevated MYC are uniquely sensitive to CDK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Self-citationBen-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Three-dimensional culture models of normal and malignant breast epithelial cells
Lee, G. Y., Kenny, P. A., Lee, E. H., & Bissell, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1015 · Cited by 1,336
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
Grandori, C., Cowley, S. M., James, L. P., & Eisenman, R. N. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.653 · Cited by 1,333
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
Voduc, K. D., Cheang, M. C. U., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9284 · Cited by 1,243
Bim: a novel member of the Bcl-2 family that promotes apoptosis
O'Connor, L. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.384 · Cited by 1,166
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
Sarrió, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., Moreno-Bueno, G., & Palacios, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2017 · Cited by 1,056
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Self-citationCyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Eilers, M., & Eisenman, R. N. (2008) · Genes & Development · doi:10.1101/gad.1712408 · Cited by 927
Liang, J., Shao, S. H., Xu, Z.-X., Hennessy, B., Ding, Z., Larrea, M., Kondo, S., Dumont, D. J., Gutterman, J. U., Walker, C. L., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1537 · Cited by 866
Self-citationModelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Weaver, V. M., Lelièvre, S., Lakins, J. N., Chrenek, M. A., Jones, J. C. R., Giancotti, F., Werb, Z., & Bissell, M. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00125-3 · Cited by 793
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Self-citationModule Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem Cells
Wong, D. J., Liu, H., Ridky, T. W., Cassarino, D., Segal, E., & Chang, H. Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.02.009 · Cited by 720
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0334 · Cited by 718
Self-citationNguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S. R., Goulet, D., Viallet, J., Bélec, L., Billot, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709443104 · Cited by 659
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 558
Epithelial-Mesenchymal Transition
Klymkowsky, M. W., & Savagner, P. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080545 · Cited by 557
Bim is a suppressor of Myc-induced mouse B cell leukemia
Egle, A., Harris, A. W., Bouillet, P., & Cory, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401471101 · Cited by 488
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
Hemann, M. T., Bric, A., Teruya-Feldstein, J., Herbst, A., Nilsson, J. A., Cordon-Cardo, C., Cleveland, J. L., Tansey, W. P., & Lowe, S. W. (2005) · Nature · doi:10.1038/nature03845 · Cited by 452
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
Gurel, B., Iwata, T., M Koh, C., Jenkins, R. B., Lan, F., Van Dang, C., Hicks, J. L., Morgan, J., Cornish, T. C., Sutcliffe, S., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.111 · Cited by 441
Esserman, L. J., Berry, D. A., DeMichele, A., Carey, L., Davis, S. E., Buxton, M., Hudis, C., Gray, J. W., Perou, C., Yau, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2779 · Cited by 438
Self-citationTriple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
The telomerase reverse transcriptase regulates chromatin state and DNA damage responses
Masutomi, K., Possemato, R., Wong, J. M. Y., Currier, J. L., Tothova, Z., Manola, J. B., Ganesan, S., Lansdorp, P. M., Collins, K., & Hahn, W. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503095102 · Cited by 382
What is triple-negative breast cancer?
Irvin, W. J., & Carey, L. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.034 · Cited by 350
Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer
Guan, Y., Kuo, W.-L., Stilwell, J. L., Takano, H., Lapuk, A. V., Fridlyand, J., Mao, J.-H., Yu, M., Miller, M. A., Santos, J. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2882 · Cited by 347
Self-citationA pathway-based classification of human breast cancer
Gatza, M. L., Lucas, J. E., Barry, W. T., Kim, J. W., Wang, Q., D. Crawford, M., B. Datto, M., Kelley, M., Mathey-Prevot, B., Potti, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912708107 · Cited by 347
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Self-citationCovalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates
Blethrow, J. D., Glavy, J. S., Morgan, D. O., & Shokat, K. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708966105 · Cited by 310
Mimicking the BH3 domain to kill cancer cells
Chonghaile, T. N., & Letai, A. (2008) · Oncogene · doi:10.1038/onc.2009.52 · Cited by 268
Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases.
Dohadwala, M., da Cruz e Silva, E. F., Hall, F. L., Williams, R. T., Carbonaro-Hall, D. A., Nairn, A. C., Greengard, P., & Berndt, N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6408 · Cited by 259
Huang, M.-J., Cheng, Y.-C., Liu, C.-R., Lin, S., & Liu, H. E. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.06.019 · Cited by 259
Development of Cell-Cycle Inhibitors for Cancer Therapy
Dickson, M. A., & Schwartz, G. K. (2009) · Current Oncology · doi:10.3747/co.v16i2.428 · Cited by 246
CDK inhibitors in cancer therapy: what is next?
Malumbres, M., Pevarello, P., Barbacid, M., & Bischoff, J. R. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.012 · Cited by 240
Multisite Phosphorylation Regulates Bim Stability and Apoptotic Activity
Hübner, A., Barrett, T., Flavell, R. A., & Davis, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.025 · Cited by 228
Non-parametric quantification of protein lysate arrays
Hu, J., He, X., Baggerly, K. A., Coombes, K. R., Hennessy, B. T. J., & Mills, G. B. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm283 · Cited by 224
Self-citationMartin, K. J., Patrick, D. R., Bissell, M. J., & Fournier, M. V. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002994 · Cited by 224
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
Gonzalez-Angulo, A. M., Stemke-Hale, K., Palla, S. L., Carey, M., Agarwal, R., Meric-Berstam, F., Traina, T. A., Hudis, C., Hortobagyi, G. N., Gerald, W. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1763 · Cited by 205
Self-citationYang, D., Liu, H., Goga, A., Kim, S., Yuneva, M., & Bishop, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008366107 · Cited by 177
Self-citationMechanism of transcriptional activation by the Myc oncoproteins
Cowling, V. H., & Cole, M. D. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.08.001 · Cited by 173
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
Molenaar, J. J., Ebus, M. E., Geerts, D., Koster, J., Lamers, F., Valentijn, L. J., Westerhout, E. M., Versteeg, R., & Caron, H. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901418106 · Cited by 167
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00113-8 · Cited by 161
Chandriani, S. J., Frengen, E., Cowling, V. H., Pendergrass, S. A., Perou, C. M., Whitfield, M. L., & Cole, M. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006693 · Cited by 155
Self-citationSchmelzle, T., Mailleux, A., Overholtzer, M., Carroll, J. S., Solimini, N. L., Lightcap, E. S., Veiby, O. P., & Brugge, J. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700115104 · Cited by 149
The c-Myc Transactivation Domain Is a Direct Modulator of Apoptotic versus Proliferative Signals
Chang, D. W.-W., Claassen, G. F., Hann, S., & Cole, M. D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.12.4309-4319.2000 · Cited by 136
Fournier, M. V., Martin, K. J., Kenny, P. A., Xhaja, K., Bosch, I., Yaswen, P., & Bissell, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0515 · Cited by 133
Self-citationPharmacodynamic Markers of Perifosine Efficacy
Hennessy, B. T., Lu, Y., Poradosu, E., Yu, Q., Yu, S., Hall, H. S., Carey, M. S., Ravoori, M. K., Gonzalez-Angulo, A. M., Birch, R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0760 · Cited by 131
Self-citationExploiting synthetic lethal interactions for targeted cancer therapy
Reinhardt, H. C., Jiang, H., Hemann, M. T., & Yaffe, M. B. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9626 · Cited by 125
Alles, M. C., Gardiner‐Garden, M., Nott, D. J., Wang, Y., Foekens, J. A., Sutherland, R. L., Musgrove, E. A., & Ormandy, C. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004710 · Cited by 109
Jain, A. N., Chin, K., Børresen‐Dale, A., Erikstein, B., Lønning, P. E., Kaaresen, R., & Gray, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151241198 · Cited by 93
Ruzinova, M. B., Caron, T. J., & Rodig, S. J. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181db83af · Cited by 83
Naidu, R., Wahab, N. A., Yadav, M., & Kutty, M. (2002) · International Journal of Molecular Medicine · doi:10.3892/ijmm.9.2.189 · Cited by 70
Seo, H. R., Kim, J., Bae, S., Soh, J., & Lee, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800987200 · Cited by 62
Nijjar, T., Bassett, E., Garbe, J. C., Takenaka, Y., Stampfer, M. R., Gilley, D. P., & Yaswen, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208482 · Cited by 50
Self-citationSierra, À., Castellsagué, X., Escobedo, A., Moreno, A., Drudis, T., & Fabra, À. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006120006471 · Cited by 29
Jones, D. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3174 · Cited by 15
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.-Y., et al. (2015) · Nature · doi:10.1038/nature15260 · Cited by 893
Self-citationAn overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
Metadata
- Authors
- Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., Yaswen, P., Mills, G. B., Esserman, L. J., & Goga, A.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-03-19
- Volume
- 209
- Issue
- 4
- Pages
- 679-696
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2118528246
- Cited by
- 378
- References
- 79
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.